| Nov 7 |
Contineum Therapeutics GAAP EPS of -$0.40
|
| Nov 6 |
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Oct 22 |
Contineum draws bullish view at Baird on de-risked assets
|
| Sep 30 |
IPO Roundup: FrontView REIT, StandardAero and more
|
| Aug 28 |
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
|
| Aug 14 |
Contineum Therapeutics GAAP EPS of -$0.39
|
| Jul 31 |
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis
|
| Jun 24 |
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
|
| Jun 13 |
Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model
|
| Jun 4 |
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
|
